Electronic Theses and Dissertations (PhDs)
Permanent URI for this collectionhttps://hdl.handle.net/10539/38222
Browse
20 results
Search Results
Item Development of an Anopheles arabiensis sex separation strain and optimisation of mosquito handling, packaging and transport conditions for the South African Mosquito Sterile Insect Technique programme(University of the Witwatersrand, Johannesburg, 2023) Mashatola, Thabo; Munhenga, Givemore; Koekemoer, LizetteSouth Africa is taking significant strides towards eliminating malaria transmission within its borders. However, existing vector control strategies that focus on indoor mosquito management face challenges with Anopheles arabiensis, the primary malaria vector. To bolster these efforts, the sterile insect technique (SIT) is being considered as an additional vector control strategy. SIT involves mass-rearing and sterilising specific pest insects, which are then released to mate with wild insects, effectively reducing the pest population. The South African SIT project faces a crucial challenge of efficiently separating female mosquitoes from the production line. This is because female mosquitoes are capable of transmitting the malaria parasite, making their elimination vital. Current methods like manual separation and resistance-based sorting have operational limitations and require further optimisation for field trials. To address this challenge, this thesis conducted optimisation and acclimatisation experiments on adult Anopheles arabiensis females, aiming to transition them to an artificial membrane feeding technique. Comparative assessments demonstrated that artificial blood-feeding methods utilising a Hemotek® membrane feeding system and hog casing could effectively replace conventional methods without significant detriment to reproductive fitness. Subsequently, the study explored the use of ivermectin, a toxicant, to spike blood during artificial feeding to target and eliminate females. An optimal concentration of ivermectin (7.5 ppm) was identified, showing potential for segregating females from males during laboratory rearing. However, complete female elimination within the desired timeframe was not achieved, indicating that this method serves as a secondary phase for female elimination. The study also investigated the use of genetic sexing strains (GSSs) to selectively eliminate females. Although efforts to induce temperature-sensitive lethal mutations temperature sensitive lethality mutations and random morphological variations were unsuccessful, further cross mating studies and insights from previous studies on thermosensitive strains from Cameroon informed future research aimed at developing GSSs tailored to the South African genetic background Another challenge addressed was the optimal temperature and compaction conditions for chilling and immobilising sterile males during handling and transport. This is crucial for maintaining the quality of sterile males. Optimal knockdown temperature ranges (4°C – 8°C for 20 minutes) and packaging conditions (1000 sterile, marked adult males per 27000 cm³ Bugdorm-1® cage) were identified for laboratory handling and transport, facilitating recent small-scale pilot trials with successful packaging and transportation of sterile males to field sites. These advancements signify significant strides in South Africa's malaria elimination endeavours, while also playing a pivotal role in shaping the development of efficient operational protocols for SIT. Furthermore, as the country remains steadfast in its commitment to eliminating malaria, these innovative approaches offer a promising trajectory forward and establish a robust framework for orchestrating the SIT operational phase.Item Equitable access to vaccines: exploring the role of accessability, acceptability, affordabilityand availability with a focus on COVID-19(University of the Witwatersrand, Johannesburg, 2024) Schwalbe, Nina; Cutland, ClareThe coronavirus disease (COVID-19) crisis brought to light many challenges, including “vaccine equity”. In other words, it raised the question: was the distribution of vaccines “fair”? While, on the one hand, there have been unprecedented advances in the science and technologies associated with vaccines, including extraordinary speed and scale-up of manufacturing, there were also significant barriers related to rollout and reaching those most at risk of severe COVID-19. These challenges have disproportionately affected low- and middle-income countries and low-income populations in high-income countries. Building on evidence from other vaccine preventable diseases, this thesis describes the challenges and opportunities concerning vaccine access with a focus on production and distribution (the “supply side”). It explores access using a “4A's” framework to conceptualise the components of access to medicines: affordability, availability, acceptability, and accessibility. The research identifies a range of access policy levers across the end-to-end process of vaccine research, development, and rollout (affordability, acceptability, accessibility, acceptability); reviews these levers as they apply to vaccine manufacturing (affordability, availability); explores the lever of financial incentives to increase coverage (acceptability); and explores the potential of using precision public health to improve vaccine impact by targeting vaccine distribution to groups most risk (accessibility). This thesis identifies several policy and program interventions ranging from regulatory harmonisation and intellectual property sharing, to using precision public health to target the delivery of vaccines to those most at risk. It also shows that while financial incentives may help, governments cannot “buy” coverage. It proposes that in future, vaccine development and deployment should start and end with a “4A’s” strategy and provides practical recommendations on how that can be achievedItem The development and value assessment of an integrated cardiovascular disease risk score in an African setting(University of the Witwatersrand, Johannesburg, 2024) Kamp, Michelle; Ramsay, Michѐle; Lewis, Cathryn; Pain, OliverCardiovascular diseases (CVD) are a significant health threat in Africa and are a leading cause of mortality and morbidity in the region. Risk stratification is the preferred approach to disease prevention but is challenging to apply due to scarce data and current scores not being validated in African populations. CVD risk is influenced by genetic and environmental factors, with the latter mostly considered in risk calculators. Precision medicine (PM) aims to tailor medical diagnostics and therapeutics by leveraging the genetics, environment, and lifestyle of individual patients. Polygenic scores (PGS) can quantify an individual’s genetic burden for CVD and improve the predictive value of risk tools when included with conventional risk factors. PGS for European ancestry populations are reaching the point where they may be useful in clinical care. However, transferability of European-derived PGS to African populations is limited and may hamper application in clinical practice. The overarching aim of the study was to develop and evaluate an integrated CVD risk score incorporating both genetic and non-genetic factors for continental African populations. This comprised of developing ancestry-aligned PGS for various cardiometabolic traits, and then deriving, evaluating, and comparing the predictive utility of genetic, non-genetic, and integrated (genetic + non-genetic) CVD risk prediction models using elastic net regression with nested 10-fold cross validation. Furthermore, we aimed to contextualise the potential utility of such PM-based tools in Africa through an assessment of the current landscape of translational genomics on the continent and by gauging clinician’s perceptions on implementing the derived CVD-risk stratification tool in South Africa’s public health setting. This study demonstrated the potential of genetic information to enhance disease risk stratification among continental African populations. Results revealed PGS provide both independent and complementary information in predicting dyslipidaemia, hypertension, and obesity - integrated scores improved prediction by at least 2.5% compared to models consisting of non-genetic factors alone. The study also highlights the challenges limiting the advancement of PM in Africa – 1. the paucity of genetic and phenotypic data within continental African populations limits the development and validation of robust and clinically useful models. This challenge is exacerbated by Euro-centric genomic and computational tools and echoes the call for more inclusive methodological approaches. 2. Despite positive perceptions of PM, there is an urgent need to address complex structural and operational barriers, including insufficient funding, lack of political will, healthcare infrastructure deficits, and training and education gapsItem Differential Gene Expression in Exfoliation Syndrome and Exfoliation Glaucoma in the Conjunctiva of Black South Africans(University of the Witwatersrand, Johannesburg, 2024) Hulley, Michaella RobynGlaucoma is a heterogeneous group of clinically and genetically complex optic neuropathies. The most prevalent identifiable secondary cause of glaucoma is the ocular manifestation of exfoliation syndrome (XFS), known as exfoliation glaucoma (XFG), a severe form of glaucoma characterized by rapid progression. While XFS is systemic, XFG is defined by fibrillar extracellular matrix (ECM) deposits in the eye. XFG has a recognised genetic aetiology, specifically with contributions from LOXL1 variants, however the molecular pathogenesis remains unclear. Conjunctival cells have not previously been used for whole transcriptome sequencing, and gene expression studies on XFG are lacking, particularly in South Africa. The aim of this study was to validate the use of conjunctival cells for whole transcriptome sequencing and interrogate the gene expression profiles of individuals with XFS and XFG. Conjunctival cells were collected from 19 cases and 15 control participants for RNA extraction, cDNA library construction and sequencing. Differential gene expression was assessed between cells from cases and controls and 81 genes were found to be differentially expressed, with 80 upregulated in cases. Interestingly, LOXL1, which has shown contradictory expression results in previous studies, was not identified as differentially expressed. The most significant overexpression was of the CCN2 gene, which encodes a matricellular protein that interacts with structural ECM molecules. A potential novel pathway involving megakaryocytes and the activation of neutrophils was, however, identified. Megakaryocytes and neutrophils are both involved with interstitial fibrosis, with neutrophils also responding to chemotactic signals to induce inflammation. The inflammatory pathway has long been associated with XFS, XFG and other fibrotic disorders, such as Alzheimer's disease and rheumatoid arthritis. Genes involved in the inflammatory process were overexpressed in XFG, including TGF-β, IL-1β, IL- 33, EGR1 and EGR3. EGR1 and EGR3 are regulated by fibrotic signals and therefore play an important role in fibrosis, which may contribute to XFS fibrillar deposits. They are also regulated by TGF-β, thus supporting a complex interplay of the inflammatory process and fibrosis in XFS pathogenesisItem The role of small genetic variants in the aetiology of developmental disorders in South Africa - a whole exome sequencing study(University of the Witwatersrand, Johannesburg, 2024) Molatoli, Mhlekazi Cathrine; Lombard, ZanéDevelopmental disorders (DD) are a diverse group of chronic conditions characterized by significant limitations to both mental and physical development. Genetic variants have been identified as the underlying aetiology in about 40-50% of DD cases. Whole exome sequencing (WES) is the recommended first-line genetic test in this group of patients and is associated with diagnostic yields of 16-45%. However, in South Africa and other resource-poor settings, karyotype testing and MLPA analysis (offering low diagnostic rates of 3% and ~9% respectively) are still being utilized for genetic testing. Thus, a higher proportion of patients remain with unexplained DD due to the limitations of these diagnostic tools and limited genetic services. The main challenge facing the clinical implementation of WES in African settings is the complex data analysis and interpretation associated with the large amount of variant data produced. This is especially challenging as African ancestry individuals have been demonstrated to have a high level of genetic diversity resulting in a higher number of novel variants reported compared to European ancestry individuals. This study seeks to investigate whether the clinical utility of WES can be replicated in an African setting. Additionally, we seek to make recommendations for variant filtering and prioritization, thus making the process of WES data analysis for DD patients more efficient. To achieve these, WES was performed in 117 patients with unexplained DD and their 180 unrelated parents. Variant data was filtered and prioritized using two in-house semi-automated pipelines. The first pipeline, prioritized variants overlapping known DD genes, as identified using the G2P-DDG2P bioinformatics analysis tool. The second pipeline identified de novo variants in trio families using the trio-dnm bioinformatics analysis tool. Sanger sequencing was used to validate low-quality prioritized variants prior to in-house interpretation and curation, and all subsequently identified putative disease-causing variants prior to reporting. Of the 117 patients from 115 families analysed, a positive molecular diagnosis was achieved for 29 families, resulting in a diagnostic yield of 25.2% (29/115). Leveraging currently available DD data, our findings demonstrate the diagnostic and clinical utility of WES which resulted in recommendations for improving patient clinical management and surveillance. This study has also developed and made recommendations for variant filtering and prioritization strategies, which can be implemented in both research and diagnostic settings to streamline and aid in the identification of putative disease-causing variants in DD patientsItem Development of a multiplex HIV/TB point-of-care diagnostic assay based on the microarray(University of the Witwatersrand, Johannesburg, 2023) Malatji, Kanyane BridgettHIV/AIDS mortality is caused by opportunistic illnesses/infections that take advantage ofthe weakened immune system in infected individuals. In Africa, the most common of these opportunistic illnesses include infection by Mycobacterium tuberculosis (M.tb) responsible for tuberculosis (TB). HIV co-infection with M.tb has negative implications for disease management given that each pathogen accelerates the morbidity caused by the other. The effective management of patients infected with both pathogens is restricted by the fact that their diagnosis is done separately. The situation is more difficult in remote areas where patients must wait for much longer to obtain their TB diagnostic results. In addition, the current diagnostic tests for the detection of TB such as chest X-ray and bacterial culture have a long turnaround time, are expensive to perform, and require sophisticated equipment and trained personnel. It is in this context that this project sought to develop an HIV and TB multiplex microarray-based assay for the detection of the two diseases using one test. The project used a 2.5 x 7.6 cm epoxy-coated glass slide as well as high- binding 96 well plates to which HIV-1 p24 and M.tb CFP10, ESAT6 and pstS1 antigens, known to be markers of active TB, were immobilized. The immobilized antigens were then incubated with anti-p24, anti-CFP10, anti-ESAT6 and anti-pstS1 primary antibodies diluted in human serum to mimic physiological conditions where the antibodies would exist in the presence of other proteins. Detection of binding between the antigens and primary antibodies was achieved by means of secondary antibodies conjugated to either a fluorescence dye or horseradish peroxidase (HRP). In chapter two of the study, the immobilization of the HIV and TB antigens on the epoxy-coated glass slides as capture molecules of the HIV and TB antibodies diluted in human serum was performed. The antigen-antibody reactions detection were achieved by means of fluorescence dye conjugated secondary antibodies. This chapter also covered the sensitivity and specificity of the technology where the epoxy-coated glass slides were compared to the gold standard 96 well high-binding plates. Data showed that the HIV and TB antigen-antibody reactions were specific, and the slides were more sensitive relative to the 96 well high-binding plates with limits of detection many folds lower. To be specific, the limit of detection from the slides averaged 0.954 ng/ml compared to 4474.6 ng/ml for the plates. The detection limit concentrations of the slides were lower than the reported physiological concentrations of HIV and TB antibodies in infected individuals. Chapter two also focused on the evaluation of the antigens’ stability on the epoxy-coated glass slides by determining the optimal experimental pH buffer, temperature, storage condition (dry or wet), as well as the shelf-life. Data showed that the optimal pH and temperature for the HIV and TB antigens immobilized on the slides were pH 7.4 and 25 ˚C. Moreover, the antigens could be stored dry for at least 90 days without losing their function. Overall, this chapter showed that the epoxy-coated microarray slides performed better than the gold standard 96 well high-binding plates in terms of sensitivity; and that the immobilized antigens could remain stable for a long period, and do not require specialized storage conditions; thus, making the microarray technology a potential diagnostic tool for the multiplex detection of HIV and TB in the case of co-infection. Chapter three of the study focused on the proof-of-concept of the technology using human serum samples infected with HIV. The chapter showed that the technology could detect p24 antibodies in six out of seven samples infected with HIV, i.e., it detected p24 antibodies in 85.7% of samples known to be HIV positive. Furthermore, HIV negative samples also proved to be negative with this technology, thus no false positives were observed. Moreover, the technology was specific for HIV detection as no binding was observed on TB antigens. Therefore, these data support what was observed in the previous chapter when the HIV antibodies were spiked in normal human serum. Chapter four explored the application of the diagnostic technology for the point-of-care (POC) detection of HIV and TB antigen- antibody reaction, using HRP conjugated secondary antibodies, as well as the 2,2′-azino- bis(3-ethylbenzothiazoline-6-sulfonicacid) (ABTS) and 3,3',5,5'-tetramethyl Benzidine (TMB) substrates for colour change based endpoint. This chapter also covered the sensitivity and specificity of the immunoassay in the high-binding 96 well plates and on epoxy-coated glass slides. Similar to what was observed in the previous chapter, the HIV and TB antigen-antibody interactions were specific, and the epoxy-coated microarray slides were more sensitive than the 96 well high-binding plates with limits of detection averaging 815-folds lower than the plates. Nevertheless, both platforms were found to be sensitive enough to be used for the POC detection of HIV and TB co infection using visual inspection. Furthermore, the stability of the antigens in the 96 well high-binding plates using colour change detection was also evaluated. The antigens were found to be stable in the high-binding plates at different pH and temperature conditions; however, pH 7.4 and 25 ˚C were optimal. In addition, the antigens were stable when stored dry in the plates for a period of three months. In addition, between the two HRP substrates used, TMB was faster and more sensitive to the HIV and TB antigen-antibody reactions than the ABTS substrate, and the difference was statistically significant (p<0.05). The importance of this chapter is that it eliminated the need for sophisticated equipment to detect the presence of HIV and TB antibodies, as the detection could be achieved by visual inspection. Overall, data in this chapter supported further development of the microarray technology for the POC HIV and TB co-infection diagnosis. Chapter five attempted to produce the CFP10, ESAT6, and pstS1 TB antigens in plants to reduce the cost associated with the current commercially available bacteria-produced antigens.Item Defining Fc-mediated Functions in People Living with HIV during Respiratory Viral Infection and Vaccination(University of the Witwatersrand, Johannesburg, 2024) Motsoeneng, Boitumelo Madika; Moore, PennyThere are approximately 39 million people living with human immunodeficiency virus (HIV) (PLWH) worldwide. Furthering our understanding of humoral immune responses to respiratory viral infection and vaccination in PLWH is essential for reducing the burden of these diseases, in high HIV prevalence settings, and informing vaccine implementation in this population. Influenza virus hemagglutinin (HA) stalk-specific antibodies have been associated with protection and shown to mediate Fc-mediated functions. This thesis describes HA stalk-specific antibody- dependent cellular phagocytosis (ADCP), cellular cytotoxicity (ADCC) and complement deposition (ADCD) between PLWH and people without HIV (PWOH) following immunization with a seasonal trivalent inactivated influenza vaccine (TIV). Irrespective of HIV status, ADCD was boosted while ADCC was not. ADCP was only enhanced in PWOH. The coordination of these functions differed by HIV status. Additionally, differences in the regulation of these HA stalk Fc responses by HIV infection was reported. Furthermore, ADCC was not associated with protection in this study. Pre- existing ADCP reduced the risk of influenza virus infection while TIV-induced ADCD provided protection against influenza-illness. Overall, PLWH have unique responses to TIV and HA stalk- specific ADCD correlated with protection following TIV. For SARS-CoV-2, antiretroviral treatment (ART)-naïve PLWH had reduced humoral responses to respiratory infection. The infecting variants D614G and Beta differentially triggered ADCC, ADCD and antibody-dependent cellular trogocytosis (ADCT). Regarding the kinetics, PLWH infected with D614G had delayed neutralization and ADCP while Beta infection delayed ADCT, regardless of HIV status. PLWH showed improved coordination between immune responses following respiratory infection. ChAdOx-1 nCoV-19 vaccination differed from infection in that PLWH had delayed IgG binding while neutralization and ADCP were not delayed, and ADCC was substantially enhanced than in PWOH. In conclusion, despite the delayed and differential kinetics, PLWH on ART developed equivalent responses to PWOH, supporting the rapid rollout of ART and SARS-CoV-2 vaccines to PLWH. This thesis highlights the need to include high-risk groups with different responses in future vaccination trials and also supports the assessment of novel correlates of protection for future vaccines. Overall, this thesis provided insights into the mechanisms required for protection against severe respiratory diseases and improved our understanding of vaccine-induced immunity in PLWHItem Defining the development of gp120-gp41 interface directed broadly neutralizing antibodies in HIV-1 infection(2024) Hlatshwayo, Vincent NkosinathiA prophylactic HIV-1 vaccine will likely need to elicit broadly neutralizing antibodies (bNAbs) against conserved HIV-1 envelope epitopes such as the gp120-gp41 interface which includes the FP. The isolation of gp120-gp41 interface-, and FP-directed bNAbs from chronically HIVinfected donors has made this epitope an appealing vaccine target. Moreover, promising preclinical immunogenicity animal studies have shown the possibility of eliciting such responses in animals. However, little is known about the population prevalence or kinetics of gp120-gp41 interface responses, including FP-directed responses. Lastly, few FP-directed antibodies have been isolated from people living with HIV (PLWH), limiting our understanding of common developmental pathways that can be explored for vaccine purposes. Here, we first assessed the prevalence of bNAbs in participants previously enrolled in the CAPRISA 004 Tenofovir gel trial (CAP004). We show that in this cohort, only 12% of individuals developed breadth at three years post-infection, and that high viral load and low CD4 count were associated with bNAb development, as previously reported. ELISA screening showed that only 13% of individuals developed FP-directed responses at three years postinfection. Of the 13% (n=9), only two donors had broad plasma responses, including donor CAP312, whose plasma exhibited 64% neutralization breadth at three years post-infection. In CAP312, FP binding and heterologous neutralization against a multi-clade 22 virus panel appeared simultaneously, within one year (~ 50 weeks post-infection). Taken together, our findings suggest that gp120-gp41 interface- and FP-directed responses are infrequently elicited during infection. As few FP-specific bNAbs have been isolated to date, little is known about their shared features that could be exploited for eliciting FP-specific bNAbs by vaccination. We next isolated three FP-specific mAbs from donor CAP312 at three years post-infection; AIRU-F8, AIRU-G9 and AIRU-G4 with 64, 45 and 5% breadth, respectively. We showed that our mAbs, and previously isolated bNAbs PGT151 and ACS202 share gene usage and have a similar unusually long CDRH3, as a result of a conserved motif inherited from the germline IGHJ6*02 gene. Furthermore, we showed that CAP312 mAbs have even longer CDRH3s compared to PGT151 and ACS202 despite this shared motif. We also showed, using point mutants and glycan mutants that our FP-specific mAbs have a unique neutralization profile compared to published mAbs. Overall, these results suggest that FP-specific mAbs share structural and genetic features that could be explored further for lineage vaccine development. Lastly, we delineated the ontogeny of the gp120-gp41 interface-directed nAb CAP248-2B by tracing the evolutionary pathways utilising longitudinal samples from 11-281 weeks postinfection (wpi). CAP248-2B interacts with the HIV-1 Env trimer through a long light chain CDRL3 that inserts into the viral membrane, and a heavy chain CDRH1 32ED33 motif that interacts with gp41. We showed that the unusually long light chain CDRL3 and the heavy chain 32ED33 motif are functionally redundant against heterologous viruses. We also showed that affinity maturation mutations in this lineage selected a lineage with limited heterologous neutralization breadth. In summary, these findings support further research into gp120-gp41- and FP-specific responses in multiple cohorts. Furthermore, future studies should aim to elucidate mechanisms governing the development of these responses so that productive developmental pathways can be identified and exploited for vaccine design.Item The changing face of thrombotic thrombocytopenic purpura: the pathophysiological role of endotheliitis and complement activation in the development of human immunodeficiency virus associated thrombotic thrombocytopenic purpura(2024) Louw, SusanIntroduction- Human Immunodeficiency virus (HIV) is a described risk factor for secondary thrombotic thrombocytopenic purpura (TTP) (HIV-TTP). The pathogenesis of this thrombotic microangiopathy (TMA) is however still unclear. The micro-thrombotic process in TTP is related to excess ultra-large von Willebrand Factor (ULVWF) multimers produced by the endothelial cells. Autoantibodies to the VWF cleaving protease, adisintegrin-and-metalloproteinase-with-thrombospondin-motifs 13 (ADAMTS-13), are postulated to be pivotal in initiating HIV-TTP. Inflammation and complement activation with resultant endothelial dysfunction and excessive release of ULVWF multimers have been implicated in other forms of TMA. These pathophysiological processes were investigated to assess the contribution to the development of HIV-TTP. Methods- Data were collected from patients presenting with HIV-TTP in an observational cohort study to delineate the routine presenting laboratory parameters and treatment outcomes. The published literature was reviewed to ascertain the documented prevalence, postulated pathogenesis and treatment outcomes of patients with HIV-TTP. An investigational study was performed in patients (n=35) presenting with HIV-TTP. In this study, patient samples were analysed for levels of endothelial activation markers (soluble intracellular adhesion molecule [sICAM] and soluble vascular adhesion molecule [sVCAM]), inflammatory cytokines (tumour necrosis factor alpha [TNF-α] and interleukin-6 [IL-6]), and complement components C3 and 4 and complement Factor H (CFH), an inhibitor of the complement pathway. Published studies were also reviewed to define the baseline biomarker levels of endothelial dysfunction and coagulation activation in people living with HIV (PLWH) without TTP to serve as points of reference. Data were collected from 2 patient cohorts with HIV infection with either disseminated intravascular coagulation (DIC) or with HIV-TTP to assess the utility of scoring systems. Results- In contrast to published literature which suggests that the prevalence of HIV-TTP is declining, this TMA is prevalent in South African PLWH in Johannesburg with heterogeneous clinical and laboratory presentation. Conventional scoring systems specifically the PLASMIC (reduced platelet count, red blood cell haemolysis, absence of cancer, no history of transplantation, reduced red blood cell volume, preservation of the international normalised ratio and creatinine) score, developed for detection of other acquired forms of TTP, performed inconsistently in the 35 patients assessed with considerable overlap with other TMAs, notably disseminated intravascular coagulation (DIC). ADAMTS-13 levels were undetectable in all patients and all patients had anti-ADAMTS-13 antibodies. The clinical presentation was, however, atypical. To delineate intermediate pathophysiological markers, the complement system, proinflammatory system and coagulation system, as well as markers of endothelial activation were analysed before and after therapeutic plasma exchange (TPE). Complement components C3 and -4 were consistently at the lower limit of the normal reference range in HIV-TTP patients at presentation. The complement regulatory protein, complement Factor H, was increased. Patients with HIV-TTP had significantly increased levels of proinflammatory cytokines when compared with published results in PLWH without comorbidities. Endothelial activation markers, sICAM and sVCAM, were also significantly increased in the HIV-TTP cohort. Importantly, D-dimer levels were also raised in this cohort of patients. Conclusions- HIV-TTP remains a cause of HIV-related morbidity and mortality in South African patients. This study reports the findings on 35 PLWH who presented to hospitals in Johannesburg with suspected TTP. The clinical presentation was inconsistent with other secondary forms of TTP i.e., minimal evidence of systemic organ dysfunction. All patients presented with schistocytosis, evidence of haemolysis and thrombocytopaenia and all had low ADAMTS-13 activity levels at presentation with detectable antiADAMTS-13 antibodies. Biomarkers of endothelial dysfunction, proinflammatory cytokine levels and markers of coagulation were all significantly increased suggesting that the pathophysiology involves complementary proinflammatory pathways which directly impact secretion of VWF from a compromised endothelium. Activation of the coagulation system, as reflected by increased D-dimer levels, specifically suggests that there may be overlap in the pathophysiology of HIV-TTP and HIV-associated DIC. A potential strategy for differentiation of these disorders with modification of scoring systems is suggested. This study provides compelling evidence of the role of the endothelium in HIV-TTP. Future directions will include validation of the biomarkers described here in more extensive cohorts as well as investigation of these biomarkers in management of these patients.Item Prognostic influence of myc aberrations and other clinicopathological factors of aggressive b-cell non-Hodgkin lymphomas(2024) Pather, SugeshneeIntroduction: Up to 30% of cancers in Africa are linked to infectious agents and in the context of the aggressive B-cell non-Hodgkin lymphomas (NHL), human immunodeficiency virus (HIV) infection is an established risk factor. Aggressive B-cell NHLs are frequently confirmed at the Chris Hani Baragwanath Academic Hospital due to the high seroprevalence of HIV infection. Therefore, an array of clinicopathological characteristics of these tumours was evaluated with the aim of identifying poor prognostic factors. Materials and methods: HIV-associated plasmablastic lymphoma (PBL), HIV-associated diffuse large B-cell lymphoma (DLBCL) and DLBCL, not otherwise specified (NOS) were included from October 2013 to June 2017. Formalin-fixed paraffin-embedded tissue sections were subjected to c-MYC immunohistochemistry (IHC), dual-colour chromogenic and fluorescence in situ hybridisation (CISH and FISH) for assessment of MYC gene rearrangement and MYC gene copy number enumeration. Thereafter, the clinicopathological characteristics were explored. Results: The study included 67 PBL patients and 63/64 (98%) were HIV-seropositive. HIVassociated PBL was typified by a mean age of 41 (standard deviation [SD] ± 10.1) years and a 54% female predominance. The patients received combination antiretroviral therapy (c-ART) prior to, or shortly after, the lymphoma diagnosis was confirmed. The median CD4 count was 170 (interquartile range [IQR] 249) cells/mm3 and 37% of the patients had CD4 counts y (P=0.02). Expression of c-MYC protein (i.e., ≥40%) occurred in 81% of PBL. Epstein-Barr virus (EBV) latent infection was detected in 90% of these tumours by utilising CISH. MYC gene aberrations included MYC rearrangement (70%) and a low-level increase in MYC gene copy numbers (43%). Concurrent MYC rearrangement with increased MYC gene copy numbers (49%) were also detected. In addition, there was low-level polysomy of chromosome (C) 8 (6%). MYC aberrations in HIV PBLs were significantly associated with a SS appearance (P=0.01), monomorphic morphology (P=0.03), c-MYC protein expression (P=0.03) and mortality (P=0.03). The median overall survival (OS) for HIV PBL was 75 days (95% CI 14–136). MYC aberrations in HIV PBL did not significantly influence the median OS [MYC+ 65 days (95% CI 0–143 days) and MYC- 71 days (95% CI 3–139 days), P=0.61] There were 22 HIV seronegative DLBCL, NOS patients (19%) with a mean age of 57 (SD ±16.7) years and a 59% male predominance. There were 93 patients (81%) with HIV-associated DLBCL, typified by a mean age of 42 (SD ±10.8) years and a 55% male predominance. The HIV seropositive patients were significantly younger at the time of presentation with lymphoma (P <0.01). c-ART was commenced prior to, or shortly after, the lymphoma diagnosis was confirmed. The median CD4 count was 162 (IQR 215) cells/mm3 and 33% of the patients had CD4 counts <100 cells/mm3 . The median viral load was 217 (IQR 182 981) copies/mL and 30% of the patients had a lower than detectable limit viral load. An advanced stage of lymphoma, i.e., stage III-IV, at presentation occurred in 87% of the patients. HIV DLBCL demonstrated a germinal centre (GC) and non-germinal centre (NGC) immunophenotypic cell of origin (COO) in 53% and 47%, respectively. Expression of c-MYC protein occurred in 58% of the HIV DLBCLs and this was significantly associated with a SS appearance (P=0.04) and high tumour proliferation indices, i.e., Ki-67 ≥90%, (P<0.01). Double expression of c-MYC and BCL2 proteins were significantly associated with the NGC COO immunophenotype (P<0.01). MYC aberrations included a low-level increase of MYC gene copy numbers (57%) and MYC rearrangements (12%). Infrequently, C8 polysomy, MYC gene clusters and concurrent MYC rearrangement with increased MYC gene copies were also identified in HIV DLBCL. The median OS was 228 days (95% CI 54–402) and 825 days (95% CI 309–1341) in the HIV seropositive and seronegative DLBCL groups, respectively (P=0.08). Compared with the HIV seronegative DLBCL group, an inferior median OS outcome occurred in the HIV seropositive group when the CD4 counts were <100 cells/mm3 (P=0.04) and when the Internal Prognostic Index (IPI) was 3–5 (P=0.01). MYC aberrations did not significantly influence the median OS [MYC+ DLBCL 155 days (95% CI 0–356) and MYC- DLBCL 154 days (95% CI 53–256), P=0.67]. In the multivariate regression analysis, the presence of concomitant infections negatively impacted the overall survival (hazard ratio 4.01 [95% CI 1.86–12.20], P=0.02).